Wait, we have a special offer for you! ✋

Get your exclusive discount now

Use FY25SAVE to get flat 20% off on the report No, I'd pay the full price

Terms & Conditions : This coupon is vaild exclusively for Global Market Reports 2025 and can be used Until March 31 , 2025 .

Global Glioblastoma Multiforme Market Report 2025

Glioblastoma Multiforme Global Market Report 2025 - By Drug Class (Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes), By Diagnostic Tools (Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types), By End-User (Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Glioblastoma Multiforme Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : March 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Glioblastoma Multiforme Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

What Is Covered Under Glioblastoma Multiforme Market

Glioblastoma multiforme (GBM) is an aggressive and fast-growing brain tumor that originates in the glial cells of the brain. It is the lethal form of primary brain cancer, characterized by rapid proliferation and resistance to standard treatments.

The main types of drug classes for glioblastoma multiforme are chemotherapy agents, temozolomide, carmustine, lomustine, and others. Chemotherapy agents for glioblastoma multiforme target and disrupt cancer cell division, helping control tumor growth and improve survival, often in combination with other treatments. It is diagnosed by various diagnostic tools such as Magnetic Resonance Imaging (MRI), computed tomography scan (CT scan), biopsy, and others and treated with several treatment types, including surgery, radiation therapy, chemotherapy, immunotherapy, tumor treating field therapy, and others. It is used by various end-users, such as hospitals, cancer research institutes, ambulatory surgical centers, and others.

How Is The Glioblastoma Multiforme Market Segmented?

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

Glioblastoma Multiforme Market Size and growth rate 2025 to 2029: Graph

What Is The Glioblastoma Multiforme Market Size 2025 And Growth Rate?

The glioblastoma multiforme market size has grown strongly in recent years. It will grow from $2.50 billion in 2024 to $2.71 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the increasing incidence of glioblastoma multiforme, rising healthcare infrastructure, increased awareness, increased access to advanced therapies, and growing aging population.

What Is The Glioblastoma Multiforme Market Growth Forecast?

The glioblastoma multiforme market size is expected to see strong growth in the next few years. It will grow to $3.69 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to an increase in cases of brain and other nervous system cancers, increasing acceptability of surgical techniques, rising awareness, early diagnosis of disease, and an increase in the number of R&D activities. Major trends in the forecast period include advances in medical technology, advancements in imaging techniques, personalized medicine, AI for diagnosis, and technological and scientific developments.

Book your 30 minutes free consultation with our research experts

Contact Us

What Is Driving The Glioblastoma Multiforme Market: Impact Of Rising Brain Disorder Cases On The Market Growth

The rising brain disorder cases are expected to drive the glioblastoma multiforme market going forward. A brain disorder is a condition that affects the structure or function of the brain, leading to cognitive, emotional, or physical impairments. Rising brain disorder cases are due to factors such as aging populations, increased life expectancy, lifestyle factors, and improved diagnostic capabilities. Understanding brain disorders helps advance research on glioblastoma multiforme (GBM), leading to better early detection, innovative treatments, and improved patient outcomes. By studying neurological conditions, scientists can uncover genetic and molecular links that contribute to GBM development. For instance, in February 2025, according to Dementia Australia, an Australia-based non-profit organization, approximately 433,300 Australians are living with dementia, with this number expected to rise to 812,500 by 2054. Additionally, younger-onset dementia affects around 29,000 people in 2025, with projections indicating an increase to 41,000 by 2054. Therefore, the rising brain disorder cases will drive the growth of the glioblastoma multiforme market.

Who Are The Major Players In The Global Glioblastoma Multiforme Market?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

What Are The Key Trends Of The Global Glioblastoma Multiforme Market: Advancements In CAR T-Cell Therapies For Glioblastoma Multiforme Treatment

Major companies operating in the glioblastoma multiforme market are focusing on developing advanced therapies, such as CAR T-cell therapies, to address the unmet medical needs of aggressive cancer. CAR T-cell therapies are a form of immunotherapy that involves modifying a patient's T-cells to target and kill cancer cells more effectively. For instance, in June 2023, Chimeric Therapeutics Limited, an Australia-based biotech company, launched a Phase IB clinical trial of CHM 1101 (CLXT CAR T) therapy for recurrent or progressive glioblastoma multiforme (GBM). The trial, conducted at multiple centers, aims to evaluate the therapy's safety and efficacy while determining the recommended Phase 2 dose. Initial Phase 1a results showed disease stability, and the trial will build on this to support further development. The company plans to use the data to design a registration trial and seek regulatory feedback.

What Are Latest Mergers And Acquisitions In The Glioblastoma Multiforme Market: ITM Isotope Technologies Partnered With Helmholtz Center Munich To Advance Glioblastoma Multiforme Treatment

In January 2022, ITM Isotope Technologies Munich SE (ITM), a Germany-based radiopharmaceutical biotech company, partnered with Helmholtz Center Munich to enhance treatment options for glioblastoma multiforme. This partnership aims to advance the clinical development of a targeted radiopharmaceutical therapy for glioblastoma multiforme, addressing a significant unmet medical need in treating this aggressive cancer. Helmholtz Center Munich is a Germany-based research center focusing on developing immunotherapy for the treatment of glioblastoma.

What Is The Regional Outlook For The Global Glioblastoma Multiforme Market?

North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the glioblastoma multiforme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Glioblastoma Multiforme  Market?

The glioblastoma multiforme market consists of revenues earned by entities by providing services such as palliative care, psychosocial support, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The glioblastoma multiforme market also includes sales of drugs, diagnostic tools, personalized medicine, and advanced drug delivery systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Glioblastoma Multiforme  Industry?

The glioblastoma multiforme market research report is one of a series of new reports from The Business Research Company that provides glioblastoma multiforme market statistics, including the glioblastoma multiforme industry global market size, regional shares, competitors with the glioblastoma multiforme market share, detailed glioblastoma multiforme market segments, market trends, and opportunities, and any further data you may need to thrive in the glioblastoma multiforme industry. This glioblastoma multiforme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Glioblastoma Multiforme Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $2.71 billion
Revenue Forecast In 2034 $3.69 billion
Growth Rate CAGR of 8.1% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The glioblastoma multiforme market covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools
3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types
4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users Subsegments:
1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2) By Temozolomide: Branded (Temodar), Generic Temozolomide
3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine), Generic Lomustine
5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Glioblastoma Multiforme Market Characteristics

    3. Glioblastoma Multiforme Market Trends And Strategies

    4. Glioblastoma Multiforme Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

    5. Global Glioblastoma Multiforme Growth Analysis And Strategic Analysis Framework

    5.1. Global Glioblastoma Multiforme PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Glioblastoma Multiforme Market Growth Rate Analysis

    5.4. Global Glioblastoma Multiforme Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Glioblastoma Multiforme Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Glioblastoma Multiforme Total Addressable Market (TAM)

    6. Glioblastoma Multiforme Market Segmentation

    6.1. Global Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Chemotherapy Agents

    Temozolomide

    Carmustine

    Lomustine

    Other Drug Classes

    6.2. Global Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Magnetic Resonance Imaging (MRI)

    Computed Tomography Scan (CT Scan)

    Biopsy

    Other Diagnostic Tools

    6.3. Global Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Surgery

    Radiation Therapy

    Chemotherapy

    Immnuotherapy

    Tumor Treating Field Therapy

    Other Treatment Types

    6.4. Global Glioblastoma Multiforme Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals

    Cancer Research Institutes

    Ambulatory Surgical Centres

    Other End-Users

    6.5. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Chemotherapy Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Alkylating Agents

    Platinum-Based Agents

    Antimetabolites

    6.6. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Temozolomide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Branded (Temodar)

    Generic Temozolomide

    6.7. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Carmustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Injectable Carmustine

    Carmustine Wafers (Gliadel)

    6.8. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Lomustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Branded (Gleostine)

    Generic Lomustine

    6.9. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Targeted Therapy

    Immunotherapy

    Tumor-Treating Fields (TTF) Therapy

    7. Glioblastoma Multiforme Market Regional And Country Analysis

    7.1. Global Glioblastoma Multiforme Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Glioblastoma Multiforme Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Glioblastoma Multiforme Market

    8.1. Asia-Pacific Glioblastoma Multiforme Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Glioblastoma Multiforme Market

    9.1. China Glioblastoma Multiforme Market Overview

    9.2. China Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Glioblastoma Multiforme Market

    10.1. India Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Glioblastoma Multiforme Market

    11.1. Japan Glioblastoma Multiforme Market Overview

    11.2. Japan Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Glioblastoma Multiforme Market

    12.1. Australia Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Glioblastoma Multiforme Market

    13.1. Indonesia Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Glioblastoma Multiforme Market

    14.1. South Korea Glioblastoma Multiforme Market Overview

    14.2. South Korea Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Glioblastoma Multiforme Market

    15.1. Western Europe Glioblastoma Multiforme Market Overview

    15.2. Western Europe Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Glioblastoma Multiforme Market

    16.1. UK Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Glioblastoma Multiforme Market

    17.1. Germany Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Glioblastoma Multiforme Market

    18.1. France Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Glioblastoma Multiforme Market

    19.1. Italy Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Glioblastoma Multiforme Market

    20.1. Spain Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Glioblastoma Multiforme Market

    21.1. Eastern Europe Glioblastoma Multiforme Market Overview

    21.2. Eastern Europe Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Glioblastoma Multiforme Market

    22.1. Russia Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Glioblastoma Multiforme Market

    23.1. North America Glioblastoma Multiforme Market Overview

    23.2. North America Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Glioblastoma Multiforme Market

    24.1. USA Glioblastoma Multiforme Market Overview

    24.2. USA Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Glioblastoma Multiforme Market

    25.1. Canada Glioblastoma Multiforme Market Overview

    25.2. Canada Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Glioblastoma Multiforme Market

    26.1. South America Glioblastoma Multiforme Market Overview

    26.2. South America Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Glioblastoma Multiforme Market

    27.1. Brazil Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Glioblastoma Multiforme Market

    28.1. Middle East Glioblastoma Multiforme Market Overview

    28.2. Middle East Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Glioblastoma Multiforme Market

    29.1. Africa Glioblastoma Multiforme Market Overview

    29.2. Africa Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Glioblastoma Multiforme Market Competitive Landscape And Company Profiles

    30.1. Glioblastoma Multiforme Market Competitive Landscape

    30.2. Glioblastoma Multiforme Market Company Profiles

    30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

    31. Glioblastoma Multiforme Market Other Major And Innovative Companies

    31.1. Novartis International AG

    31.2. Eli Lilly and Company

    31.3. Amgen Inc.

    31.4. Merck KGaA

    31.5. Teva Pharmaceutical Industries Ltd.

    31.6. Sun Pharmaceutical Industries Ltd.

    31.7. Zydus Pharmaceuticals (USA) Inc.

    31.8. Accord Healthcare Inc.

    31.9. Sumitomo Dainippon Pharma Oncology Inc.

    31.10. Karyopharm Therapeutics Inc.

    31.11. ITM Isotope Technologies Munich SE

    31.12. Azurity Pharmaceuticals Inc.

    31.13. Genenta Science S.p.A.

    31.14. Chimeric Therapeutics Limited

    31.15. VBI Vaccines Inc.

    32. Global Glioblastoma Multiforme Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Glioblastoma Multiforme Market

    34. Recent Developments In The Glioblastoma Multiforme Market

    35. Glioblastoma Multiforme Market High Potential Countries, Segments and Strategies

    35.1 Glioblastoma Multiforme Market In 2029 - Countries Offering Most New Opportunities

    35.2 Glioblastoma Multiforme Market In 2029 - Segments Offering Most New Opportunities

    35.3 Glioblastoma Multiforme Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Glioblastoma Multiforme Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Chemotherapy Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Temozolomide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Carmustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Lomustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Glioblastoma Multiforme Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Glioblastoma Multiforme Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Pfizer Inc. Financial Performance
  • Table 81: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 82: AbbVie Inc. Financial Performance
  • Table 83: Bristol Myers Squibb Company Financial Performance
  • Table 84: AstraZeneca PLC Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Glioblastoma Multiforme Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Chemotherapy Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Temozolomide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Carmustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Lomustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Glioblastoma Multiforme Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Glioblastoma Multiforme Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Pfizer Inc. Financial Performance
  • Figure 81: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 82: AbbVie Inc. Financial Performance
  • Figure 83: Bristol Myers Squibb Company Financial Performance
  • Figure 84: AstraZeneca PLC Financial Performance

Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis

Read More

How Will The Nuclear Medicine Market Grow In 2022?

Read More

What Is The Pediatric Imaging Market Overview In 2022?

Read More

Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company

Read More

The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the rcm market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the medical tourism market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the clinical chemistry market market research report 2022 with industry size, share, segments and market growth

Read More

Brain Implants Global Market Report 2024 – By Product (Deep Brain Stimulator, Spinal Cord Stimulator, Vagus Nerve Stimulator), By Application (Chronic Pain, Epilepsy, Parkinson’s Disease, Depression, Essential Tremor, Alzheimer’s Disease), By End User (Hospitals, Neurology Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Glioblastoma Multiforme (GBM) Treatment Global Market Report 2025 – By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy), By Drug Class (Temozolomide, Bevacizumab, Lostine, Carstone Wafers, Other Drug Classes), By Route of Administration (Oral, Parenteral, Other Route Of Administrations), By End-Use (Hospitals, Clinics, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Spinal Surgery Devices And Equipment Global Market Report 2025 – By Product Type (Non-Fusion Devices, Fusion Devices, Equipment), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Orthopedic And Spine Centers), By Type Of Surgery (Open Surgery And Minimally Invasive Surgery (MIS)) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Cerebrospinal Fluid Management (CSF) Devices And Equipment Global Market Report 2025 – By Type (CSF Shunts, CSF Drainage Systems), By Age group (Pediatric, Adult, Geriatric), By End User (Hospitals, Ambulatory surgical centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Spinal Imaging Global Market Report 2025 – By Product (X-Ray, CT, MRI, Ultrasound), By Application (Spinal Infection, Vertebral Fractures, Spinal Cancer, Spinal Cord and Nerve Compressions, Other Applications), By End-User (Hospital, Diagnostic Imaging Center, Ambulatory Care Center) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Spinal Cord Stimulation Global Market Report 2025 – By Product (Rechargeable, Non-rechargeable), By Application (Failed Back Surgery Syndrome (FBSS), Degenerative Disc Disease (DDD), Complex Regional Pain Syndrome (CRPS), Arachnoiditis, Other Disease Indications), By End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Acute Spinal Cord Injury Global Market Report 2025 – By Type (Complete Spinal Cord Injury, Incomplete Spinal Cord Injury), By Diagnosis Type (Laboratory Tests, Imaging Tests), By Application (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Traumatic Brain Injury Global Market Report 2025 – By Device (Computed Tomography, X-Ray, Imaging Devices, Magnetic Resonance Imaging Devices, Monitoring Devices, Other Devices), By Technique (Intracranial Pressure (ICP) Monitoring, Partial Pressure Of Oxygen In Brain Tissue (PbrO,), By End-Use (Diagnostic Centers, Hospitals, Other End-Uses) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Glioblastoma Multiforme market?

Glioblastoma multiforme (GBM) is an aggressive and fast-growing brain tumor that originates in the glial cells of the brain. It is the lethal form of primary brain cancer, characterized by rapid proliferation and resistance to standard treatments. For further insights on the Glioblastoma Multiforme market, request a sample here

How will the Glioblastoma Multiforme market drivers and restraints affect the market dynamics? What forces will shape the Glioblastoma Multiforme industry going forward?

The Glioblastoma Multiforme market major growth driver - Impact Of Rising Brain Disorder Cases On The Market Growth. For further insights on the Glioblastoma Multiforme market, request a sample here

What is the forecast market size or the forecast market value of the Glioblastoma Multiforme market?

The Glioblastoma Multiforme market size has grown strongly in recent years. The glioblastoma multiforme market size has grown strongly in recent years. It will grow from $2.50 billion in 2024 to $2.71 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the increasing incidence of glioblastoma multiforme, rising healthcare infrastructure, increased awareness, increased access to advanced therapies, and growing aging population. The glioblastoma multiforme market size is expected to see strong growth in the next few years. It will grow to $3.69 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to an increase in cases of brain and other nervous system cancers, increasing acceptability of surgical techniques, rising awareness, early diagnosis of disease, and an increase in the number of R&D activities. Major trends in the forecast period include advances in medical technology, advancements in imaging techniques, personalized medicine, AI for diagnosis, and technological and scientific developments. For further insights on the Glioblastoma Multiforme market, request a sample here

How is the Glioblastoma Multiforme market segmented?

The glioblastoma multiforme market covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools
3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types
4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:
1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2) By Temozolomide: Branded (Temodar), Generic Temozolomide
3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine), Generic Lomustine
5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy For further insights on the Glioblastoma Multiforme market, request a sample here

Which region has the largest share of the Glioblastoma Multiforme market? What are the other regions covered in the report?

North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Glioblastoma Multiforme market, request a sample here.

Who are the major players in the Glioblastoma Multiforme market?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc. . For further insights on the Glioblastoma Multiforme market, request a sample here.

What are the key trends in the Glioblastoma Multiforme market?

Major trends in the Glioblastoma Multiforme market include Advancements In CAR T-Cell Therapies For Glioblastoma Multiforme Treatment. For further insights on the Glioblastoma Multiforme market, request a sample here.

What are the major opportunities in the Glioblastoma Multiforme market? What are the strategies for the Glioblastoma Multiforme market?

For detailed insights on the major opportunities and strategies in the Glioblastoma Multiforme market, request a sample here.

How does the Glioblastoma Multiforme market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Glioblastoma Multiforme market growth and SWOT analysis of the Glioblastoma Multiforme industry, request a sample here.

For detailed insights on Glioblastoma Multiforme's relation to the overall economy and other similar markets,

What are the latest mergers and acquisitions in the Glioblastoma Multiforme industry? request a sample here.

For detailed insights on the mergers and acquisitions in the Glioblastoma Multiforme industry,

What are the key dynamics influencing the Glioblastoma Multiforme market growth? SWOT analysis of the Glioblastoma Multiforme market. request a sample here.